The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...